Journal Watch · ACS Nano · 2026
Mosaic Inverted Hemagglutinin Extracellular Vesicle Vaccines Elicit Protective Systemic and Mucosal Immunity against Heterosubtypic Influenza Infection.
EV-based mosaic HA vaccines hold great promise for developing universal influenza vaccines that target a mucosal route.
TL;DR
EV-based mosaic HA vaccines hold great promise for developing universal influenza vaccines that target a mucosal route.
Key findings
- EV-based mosaic HA vaccines hold great promise for developing universal influenza vaccines that target a mucosal route.
What they did
Immunization with the mosaic HA-EV vaccine elicited cross-reactive antibodies against influenza HA stalks and viruses, robust virus-specific cellular immune responses, and a balanced Th1/Th2 immune profile. Notably, the EVs demonstrated a promising application as an effective mucosal vaccine strategy, as evidenced by enhanced HA stalk- and virus-specific IgA in mucosal tissues and complete protection against heterosubtypic reassortant H7N9 and H5N1 virus infections in mice via intranasal immunization.
Full abstract (original)
Background: Developing innovative vaccine platforms and delivery strategies to induce broad, protective immunity in the respiratory tract is crucial for preventing influenza infection and transmission in potential epidemics and pandemics. In this study, we used cell-derived extracellular vesicles (EVs) as a vaccine platform to display mosaic human and avian influenza hemagglutinins (HAs) concurrently, including HA1/HA9/HA12 or HA3/HA4/HA10, on the EV surfaces.
What they did: Immunization with the mosaic HA-EV vaccine elicited cross-reactive antibodies against influenza HA stalks and viruses, robust virus-specific cellular immune responses, and a balanced Th1/Th2 immune profile. Notably, the EVs demonstrated a promising application as an effective mucosal vaccine strategy, as evidenced by enhanced HA stalk- and virus-specific IgA in mucosal tissues and complete protection against heterosubtypic reassortant H7N9 and H5N1 virus infections in mice via intranasal immunization.
Results & conclusions: EV-based mosaic HA vaccines hold great promise for developing universal influenza vaccines that target a mucosal route.
Abstract © the authors / ACS Nano (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acsnano.5c13363 · PubMed 41920585.
Why it matters for pharma & biotech
- Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: vaccines
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this ACS Nano study find?
EV-based mosaic HA vaccines hold great promise for developing universal influenza vaccines that target a mucosal route.
What type of study is this?
It is a preclinical (animal / model) study, published in ACS Nano in 2026. Immunization with the mosaic HA-EV vaccine elicited cross-reactive antibodies against influenza HA stalks and viruses, robust virus-specific cellular immune responses, and a balanced Th1/Th2 immune profile.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acsnano.5c13363. PubMed ID: 41920585. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/mosaic-inverted-hemagglutinin-extracellular-vesicle-vaccines-elicit-prot-c13363/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides